Recent Updates
Recently added Catalysts
DCTH Positive Sentiment

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Monday, October 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Delcath Systems, Inc. is set to present its clinical development programs at the ESMO Congress 2026 in Madrid. The company is emphasizing its focus on treating liver cancers and has published independent analysis on percutaneous hepatic perfusion. This highlights their ongoing commitment to advancing oncology treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Delcath Systems is actively participating in ESMO Congress 2026.
  • The company is focusing on innovative treatments for liver cancers.
  • Independent data on percutaneous hepatic perfusion has been published.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+82%
120-day peak, hindsight
Typical move
41.6%
average across 2 past catalysts
Lead asset
Hepzato Kit (melphalan HDS)
Phase 2 · Refractory Metastatic Colorectal Cancer

Full Press Release Details

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) w

Frequently Asked Questions

What is the focus of Delcath Systems?

Delcath Systems focuses on interventional oncology for liver cancers.

When is the ESMO Congress 2026 taking place?

The ESMO Congress 2026 is scheduled for October 23–27 in Madrid, Spain.

What data is Delcath Systems highlighting?

Delcath is highlighting independent analysis on percutaneous hepatic perfusion.

Where will Delcath present its findings?

Delcath will present its findings at the ESMO Congress 2026.

ShareAdd on Google
Tags: DCTH Delcath Systems ESMO Congress 2026 liver cancer percutaneous hepatic perfusion
Last updated: Oct 19, 2026

Biotech snapshot

Cash runway
$96M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Hepzato Kit (melphalan HDS)Phase 2
Refractory Metastatic Colorectal Cancer →

Catalyst track record

+82%
best trade around DCTH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DCTH.

See every catalyst's timing & PoA →